Media stories about Teleflex (NYSE:TFX) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Teleflex earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the medical technology company an impact score of 47.411061583569 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Teleflex (NYSE:TFX) traded up $2.59 during mid-day trading on Friday, reaching $263.18. The company had a trading volume of 177,527 shares, compared to its average volume of 276,821. Teleflex has a 12-month low of $162.79 and a 12-month high of $271.23. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88. The stock has a market cap of $11,860.00, a price-to-earnings ratio of 47.51, a P/E/G ratio of 1.92 and a beta of 1.09.
Teleflex (NYSE:TFX) last posted its earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm had revenue of $534.70 million for the quarter, compared to analyst estimates of $522.94 million. During the same quarter in the prior year, the company earned $1.80 EPS. Teleflex’s revenue was up 17.3% on a year-over-year basis. analysts anticipate that Teleflex will post 8.36 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Wednesday, November 15th were paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a yield of 0.52%. The ex-dividend date of this dividend was Tuesday, November 14th. Teleflex’s payout ratio is currently 24.55%.
TFX has been the topic of several research analyst reports. Stephens reissued a “buy” rating and set a $270.00 price target (up previously from $230.00) on shares of Teleflex in a research note on Monday, September 25th. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $265.00 price target on the stock in a research note on Friday, September 22nd. Jefferies Group boosted their price target on Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Needham & Company LLC boosted their price target on Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Finally, Deutsche Bank reissued a “buy” rating and set a $251.00 price target (up previously from $238.00) on shares of Teleflex in a research note on Monday, September 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $274.44.
In related news, CEO Benson Smith sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the sale, the chief executive officer now owns 76,634 shares of the company’s stock, valued at approximately $19,779,235.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $248.96, for a total value of $49,792.00. Following the completion of the sale, the director now directly owns 8,080 shares in the company, valued at approximately $2,011,596.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,600 shares of company stock worth $666,492. 2.39% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: “Teleflex (TFX) Given Daily News Sentiment Rating of 0.10” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/teleflex-tfx-given-daily-news-sentiment-rating-of-0-10.html.
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.